Overview: progression-free survival as an endpoint in clinical trials with solid tumors.
about
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trialsA Review of Modeling Approaches to Predict Drug Response in Clinical OncologyFrench Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.The imaging viewpoint: how imaging affects determination of progression-free survivalPopulation pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.The power of phase II end-points for different possible mechanisms of action of an experimental treatmentOvarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.RECIST - learning from the past to build the future.Another disappointing result, but how good is it?Survival analyses in lung cancer.Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.A methodology to extract outcomes from routine healthcare data for patients with locally advanced non-small cell lung cancer.Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
P2860
Q26797292-8CF5E929-50D2-4499-A091-7B8732CF9148Q28066777-A1A5E0AB-05BB-4572-9D14-8E39D775F31AQ30384043-79C13CF5-7C7E-467A-AB44-25329610853FQ33567889-20686931-93F7-4413-B13F-4F45FB0F9E60Q34040130-42025604-55F8-412E-93D8-E101B628E619Q34719348-8F23BC9C-DFCE-49EE-9C1B-DCD61747CE55Q34953673-9FEE333C-19F3-4902-8ACD-76273E7F3BA8Q35619065-B39645B5-0912-42BF-A8A1-E6884E520695Q36433053-4B067013-F040-45D2-99D9-E6A33E52D7FBQ38780372-1CE2A473-7250-46F2-A2AC-05BA114313F3Q42332732-163C4FF2-986C-4250-94AA-B5F3B50CEDE0Q42344282-0041B662-504E-4703-95CB-5C328FF9C95AQ47691581-529930C9-CA95-4B1F-92EE-BBAA67676D58Q52593429-40EFFE94-7767-42EB-90BF-432E670AD332Q52627357-DF8AABAD-106D-45D8-83DF-E596A34B93C8
P2860
Overview: progression-free survival as an endpoint in clinical trials with solid tumors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overview: progression-free survival as an endpoint in clinical trials with solid tumors.
@en
type
label
Overview: progression-free survival as an endpoint in clinical trials with solid tumors.
@en
prefLabel
Overview: progression-free survival as an endpoint in clinical trials with solid tumors.
@en
P2860
P1476
Overview: progression-free survival as an endpoint in clinical trials with solid tumors.
@en
P2093
John J Crowley
Ronald L Korn
P2860
P304
P356
10.1158/1078-0432.CCR-12-2934
P407
P577
2013-05-01T00:00:00Z